Zhang Chang-Hong, Liu Jian-Hua, Zhao Jian-Qing, Zhang Zhi-Hua, Gu Xin
Chang-hong Zhang, Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Hebei North University, Zhangjiakou 075000, Hebei, China.
Jian-hua Liu, Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Hebei North University, Zhangjiakou 075000, Hebei, China.
Pak J Med Sci. 2023 Sep-Oct;39(5):1502-1506. doi: 10.12669/pjms.39.5.7259.
To investigate the effect of bi-level positive airway pressure (BIPAP) therapy on chronic obstructive pulmonary disease (COPD) complicated with anxiety and depression.
This is a retrospective study. One hundred patients with COPD complicated with anxiety and depression who were admitted to the Respiratory Department of The First Affiliated Hospital of Hebei North University from August 2021 to August 2022 were selected and randomly divided into two groups. Patients in the control group were given conventional symptomatic treatment, while those in the observation group were given BIPAP therapy in addition to the treatment in the control group. The two groups were compared and analyzed in terms of respiratory function indicators, the changes in the scores of St. George's Hospital Respiratory Questionnaire (SGRQ) and COPD assessment test (CAT), blood gas analysis indicators, the levels of serum neurokinin A (NKA), serum interleukin-6 (IL-6), and serum serotonin (5-HT), as well as the changes in the scores of Hamilton Anxiety Scale (HAMA) and Hamilton Depression Scale (HAMD).
After treatment, the levels of lung function indicators in both groups increased, SGRQ and CAT scores decreased, and pH levels remained unchanged. In addition, PaO levels increased, PCO, 5-HT, NKA and IL-6 levels decreased, and HAMA and HAMD scores decreased. The improvement degree of each indicator in the observation group was superior to that in the control group.
In the clinical treatment of COPD complicated with anxiety and depression, BIPAP boasts effective amelioration of lung function and relief of anxiety and depression symptoms, and its mechanism of action may have a close bearing on ameliorating the levels of 5-HT, NKA, and IL-6 in patients.
探讨双水平气道正压通气（BIPAP）治疗对慢性阻塞性肺疾病（COPD）合并焦虑抑郁的影响。
本研究为回顾性研究。选取2021年8月至2022年8月在河北北方学院附属第一医院呼吸内科住院的100例COPD合并焦虑抑郁患者，随机分为两组。对照组给予常规对症治疗，观察组在对照组治疗基础上给予BIPAP治疗。比较分析两组患者的呼吸功能指标、圣乔治医院呼吸问卷（SGRQ）和慢性阻塞性肺疾病评估测试（CAT）评分变化、血气分析指标、血清神经激肽A（NKA）、血清白细胞介素-6（IL-6）和血清5-羟色胺（5-HT）水平，以及汉密尔顿焦虑量表（HAMA）和汉密尔顿抑郁量表（HAMD）评分变化。
治疗后，两组患者肺功能指标水平均升高，SGRQ和CAT评分降低，pH值水平无变化。此外，动脉血氧分压（PaO）水平升高，二氧化碳分压（PCO）、5-HT、NKA和IL-6水平降低，HAMA和HAMD评分降低。观察组各指标改善程度优于对照组。
在COPD合并焦虑抑郁的临床治疗中，BIPAP能有效改善肺功能，缓解焦虑抑郁症状，其作用机制可能与改善患者5-HT、NKA和IL-6水平密切相关。
